JPMorgan Chase & Co. Increases TG Therapeutics (NASDAQ:TGTX) Price Target to $43.00

TG Therapeutics (NASDAQ:TGTX) had its target price boosted by equities researchers at JPMorgan Chase & Co. from $30.00 to $43.00 in a report released on Monday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 20.18% from the company’s previous close.

Several other brokerages also recently commented on TGTX. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, B. Riley lifted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Up 2.0 %

TGTX opened at $35.78 on Monday. The business has a 50-day moving average of $25.62 and a two-hundred day moving average of $21.70. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics has a 12 month low of $12.30 and a 12 month high of $36.50. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of -357.76 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same period last year, the business posted $0.73 earnings per share. On average, research analysts expect that TG Therapeutics will post 0.17 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors have recently made changes to their positions in the stock. NBC Securities Inc. boosted its position in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the period. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in shares of TG Therapeutics during the second quarter worth about $35,000. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics in the 3rd quarter worth about $53,000. Finally, Values First Advisors Inc. bought a new stake in TG Therapeutics in the 3rd quarter valued at about $58,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.